Liquidia Co. (NASDAQ:LQDA) CFO Sells $45,722.88 in Stock

Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta sold 3,136 shares of the firm’s stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $14.58, for a total transaction of $45,722.88. Following the transaction, the chief financial officer now owns 315,045 shares of the company’s stock, valued at approximately $4,593,356.10. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Michael Kaseta also recently made the following trade(s):

• On Monday, March 18th, Michael Kaseta sold 12,166 shares of Liquidia stock. The stock was sold at an average price of $15.82, for a total transaction of $192,466.12.

Liquidia Stock Down 3.8 %

Shares of LQDA stock opened at $13.29 on Friday. Liquidia Co. has a 52 week low of $5.71 and a 52 week high of $16.99. The firm has a 50 day moving average of $14.74 and a 200-day moving average of $10.97.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Wednesday, March 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.19). Liquidia had a negative net margin of 448.89% and a negative return on equity of 132.16%. The business had revenue of $4.53 million during the quarter, compared to analyst estimates of $5.29 million. Research analysts expect that Liquidia Co. will post -1.01 EPS for the current year.

Institutional Trading of Liquidia

Several hedge funds have recently bought and sold shares of LQDA. Fortitude Family Office LLC acquired a new stake in Liquidia in the 4th quarter valued at $26,000. UBS Group AG grew its position in Liquidia by 134.0% in the 2nd quarter. UBS Group AG now owns 7,948 shares of the company’s stock valued at $35,000 after purchasing an additional 4,552 shares during the period. Legal & General Group Plc acquired a new stake in Liquidia in the 2nd quarter valued at $38,000. BNP Paribas Arbitrage SA grew its position in Liquidia by 42.8% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 10,682 shares of the company’s stock valued at $47,000 after purchasing an additional 3,200 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in Liquidia by 101.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,004 shares of the company’s stock valued at $55,000 after purchasing an additional 3,524 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of Liquidia in a report on Wednesday, April 10th. HC Wainwright raised their price objective on shares of Liquidia from $16.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, March 14th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).